U nder basal conditions, ≈90% of the resistance to blood flow in the heart occurs in the small arteries and arterioles that make up the coronary microcirculation. 1 Microvascular resistance is primarily determined by vessel density and lumen diameter. The latter is highly dynamic in the healthy heart and facilitates large changes in flow to meet increases in myocardial oxygen consumption during stress. Variations in the vascular tone of coronary microvessels results from vasodilator and vasoconstrictor signals that arise in response to physical forces, neurohormonal, and endothelium-derived substances, as well as metabolic mediators released from cardiac myocytes. Of these, vasodilation from increased shear stress or flow-induced dilation provides an important means of communication among various segments of the vasculature to regulate changes in local perfusion more accurately. 2 An increasing number of studies have demonstrated that coronary microvascular dysfunction can contribute to precipitating myocardial ischemia and ventricular dysfunction in the absence of coronary artery disease (CAD). 3, 4 Of equal importance, impaired flow-induced responses predict cardiovascular events in patients with established cardiovascular disease, as well as in asymptomatic subjects. 5
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Although flow-induced dilation requires an intact endothelium, the biochemical mediators of dilation vary by organ, species, vessel size, age, and disease status. For example, in juvenile porcine coronary resistance vessels, nitric oxide (NO) mediates flow-induced dilation, 6 yet flow-induced dilation is mediated by a hyperpolarizing factor in epicardial conduit arteries. 7 In humans, prostaglandins mediate flow-induced dilation of coronary arterioles from children, 2 whereas NO is the primary mediator of flow-induced dilation in normal adults. The presence of CAD or cardiovascular risk factors increases oxidative stress, reduces NO bioavailability, and diminishes the role of NO. 8 Despite this, flow-induced dilation in humans can be maintained by mechanisms that compensate for the loss of NO. Miura et al 9 demonstrated that hydrogen peroxide (H 2 O 2 ), an endothelium-derived hyperpolarizing factor, is released in response to shear stress and preserves flow-induced arteriolar vasodilation in coronary arterioles from patients with CAD. Subsequent studies demonstrated that H 2 O 2 is produced in the mitochondria 10 and elicits vasodilation via the activation of BK Ca channels on vascular smooth muscle. 11 Collectively, these studies support a paradigm where aging and disease herald a switch in the mechanism of coronary arteriolar flow-induced vasodilation from endothelium-derived NO to endothelium-derived H 2 O 2.
2 This transition may be beneficial in maintaining flow-induced dilation and in regulating local myocardial blood flow, but it likely comes at a cost. NO has anti-inflammatory, antiproliferative, and antithrombotic effects that protect against the development of vascular dysfunction and atherosclerotic disease. 12 In contrast, H 2 O 2 is a reactive oxygen intermediate involved in pathophysiological processes, such as inflammation, ischemia/reperfusion injury, and atherosclerosis. 2, 13 Because of these divergent cellular actions, manipulating the transition in mediators of flow-induced dilation between NO and H 2 O 2 could afford a potential therapeutic target for the treatment of cardiovascular disease.
In the present issue of Circulation Research, Freed et al 14 shed new light on the mechanisms underlying plasticity of the biochemical mediators of flow-induced vasodilation in the human coronary microcirculation. In a series of well-conceived experiments using adipose and atrial resistance arterioles isolated from healthy and diseased human subjects, they demonstrate that ceramide, a sphingolipid, plays a key role in affecting the transition of flow-induced dilation from NO to H 2 O 2 in CAD. Consistent with studies supporting the role of NO in normal animals and humans, the l-arginine analogue L-NAME abolished flow-induced vasodilation of adipose arterioles from healthy adults. Interestingly, overnight in vitro incubation of arterioles with exogenous ceramide did not alter the magnitude of flow-induced dilation but switched the mediator from NO to H 2 O 2 . In contrast to healthy adults, flow-induced dilation of adipose arterioles obtained from patients with chronic CAD was mediated by H 2 O 2. Overnight incubation of these vessels with an inhibitor of the ceramide-producing enzyme, neutral sphingomyelinase, re-established NO as the mechanism of flow-induced vasodilation, a finding also observed in atrial arterioles from patients with CAD. The data indicate that ceramide plays a central role in rapidly switching the mediator of flow-induced dilation from NO to H 2 O 2 that can be manipulated in a bidirectional fashion.
These findings provide novel mechanistic insight into how the transition between NO and H 2 O 2 occurs in CAD. The fact that they were made in human arterioles is significant in light of the species-related variability in flow-induced vasodilation 
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and underscores their translational relevance in advancing our understanding of human pathophysiology. The brief (16-20 hours) time-frame required to switch from NO to H 2 O 2 in ceramide-treated vessels (and back to NO with sphingomyelinase inhibition) is particularly interesting. As the authors point out, understanding the role of ceramide signaling in the rapid switching of vasodilator mechanisms warrants further investigation because this may identify new therapeutic approaches to treat microvascular disease. The results add to the growing body of evidence implicating ceramide accumulation as a critical regulator of cardiovascular pathophysiology. 15, 16 Ceramide and other sphingolipids were previously thought to serve a structural role as integral components of biological membranes simply. More recently, it has become clear that sphingolipids are also involved in signal transduction and regulating various cellular processes. Although intracellular ceramide can be formed de novo in the endoplasmic reticulum, the primary source is hydrolysis of sphingomyelin by sphingomyelinases. 17 In the cardiovascular system, in vitro studies have shown that ceramide accumulation occurs in several pathophysiological conditions. For example, tumor necrosis factor-α and oxidized low-density lipoprotein increase ceramide in endothelium and vascular smooth muscle, whereas ischemia/reperfusion injury and doxorubicin-induced cardiotoxicity increase ceramide in cardiomyocytes. 18 Ceramide has also received attention for its role in apoptotic signaling, as well as modulation of cell proliferation, migration, and adhesion, with divergent actions depending on cell type. 17, 19, 20 It is important to note that the switch to H 2 O 2 as a mechanism of flow-induced vasodilation in isolated human arterioles 9, 11, 14 is not seen in animal models of atherosclerosis. Kuo et al 21 observed impaired endothelium-dependent vasodilation to several pharmacological agonists, as well as shear stress, in arterioles isolated from pigs with diet-induced atherosclerosis. The impairment was NO dependent and was not associated with compensatory upregulation of alternative vasodilator pathways because flow-induced dilation was completely abolished in these vessels. Although endothelium-derived hyperpolarizing factor compensation to maintain acetylcholine-induced vasodilation was observed in isolated carotid artery segments of hypercholesterolemic rabbits, 22 evidence of a disease-mediated or risk factor-mediated compensatory switch in microcirculatory vessels is lacking. It is unclear whether this is because the plasticity of vasodilatory mechanisms in disease states is unique to humans or because young animals, with potentially different mechanisms of vasomotor regulation than their older counterparts, are typically studied. Regardless, this conundrum may make it difficult to pursue further investigation of the role of ceramide in regulating flow-induced vasodilation in experimental models of atherosclerosis, emphasizing the importance of conducting future studies of the human coronary circulation.
From a translational perspective, the observation that neutral sphingomyelinase inhibition restores NO as the mediator of flow-induced vasodilation in arterioles from patients with CAD is particularly exciting because it suggests that manipulation of ceramide biosynthesis could provide a new approach to restore endothelial function in patients with vascular disease. Although this may be difficult because of the plethora of signaling actions attributed to ceramide and related sphingolipids, pharmacological approaches to manipulate tissue ceramide levels have been investigated. 19 One approach may involve restoration of tissue glutathione concentrations. Reduced glutathione levels increase neutral sphingomyelinase activity and ceramide accumulation. 16, 23 Administration of the glutathione precursors N-acetylcysteine and α-lipoic acid reduce sphingomyelinase activity and improve endothelium-dependent vasodilation of isolated aortic rings from aged rats. 18, 24 Additional studies will be necessary to test whether restoration of glutathione concentrations in human coronary arterioles can restore NO as the mediator of flow-induced vasodilation.
How do these in vitro observations relate to integrative coronary circulatory control? The shift from NO to H 2 O 2 and preservation of flow-induced vasodilation in isolated human coronary arterioles in vitro contrasts with impaired coronary flow responses in patients with CAD risk factors and no epicardial coronary disease. In other words, the compensatory upregulation of H 2 O 2 -mediated dilation seems to be insufficient to maintain flow reserve in patients in vivo. It is possible that the compensatory response only occurs in a specific segment of the coronary microcirculation, whereas impaired flow-mediated responses in smaller arterioles or proximal coronary vessels persist. An alternative possibility is that structural alterations of coronary resistance arteries and arterioles impair minimal coronary vascular resistance in situ. Recent studies have shown that the coronary microcirculation can undergo a variety of structural changes in different pathophysiologic states. 25 Structural alterations (Figure) may increase minimum A B Figure. Schematic representation of potential ceramidemediated structural and functional effects on the coronary microcirculation. In healthy subjects (A), an increase in flow through a coronary arteriole elicits flow-induced dilation mediated by endothelium-derived nitric oxide. Ceramide accumulation occurs with the development of coronary artery disease (B), promoting a switch in the mediator of flow-induced dilation from nitric oxide to hydrogen peroxide. In addition, ceramide signaling elicits proliferation of vascular smooth muscle cells, contributing to arteriolar structural remodeling characterized by increased wall thickness and reduced lumen diameter. Although the compensatory upregulation of hydrogen peroxide-mediated vasodilation preserves the relative magnitude of flow-induced dilation, structural changes limit the absolute dilatory capacity of the vessel, resulting in an increased minimum coronary vascular resistance that limits coronary flow reserve. vascular resistance of the microcirculation because of a reduction in luminal diameter (ie, inward remodeling). Importantly, even a small reduction in lumen diameter (which may be difficult to quantify) would significantly increase microcirculatory resistance because this varies with the fourth power of vessel diameter. Structural remodeling of resistance arteries is supported by Freed et al. 14 Representative images of arterioles from patients with CAD show hypertrophic inward remodeling characterized by an increased wall thickness and a concomitant reduction in luminal diameter. Interestingly, ceramide accumulation occurred in the thickened medial layer of these vessels, indicating potentially important effects on vascular smooth muscle proliferation. This possibility is also supported by data from Auge et al, 26 implicating ceramide signaling in smooth muscle cell proliferation after exposure to oxidized low-density lipoprotein. Finally, Ohanian et al 27 recently observed age-related hypertrophic remodeling in sheep resistance arteries that was accompanied by an increase in sphingomyelinase activity and accumulation of long-chain ceramides. On the basis of these considerations, ceramide signaling in the microcirculation may be a 2-edged sword, with maintenance of flow-induced dilation via upregulation of H 2 O 2 counteracted by adverse structural remodeling of coronary microvessels.
The demonstration that short-term ceramide exposure rapidly switches the mediator of flow-induced vasodilation from NO to H 2 O 2 by Freed et al 14 advances our understanding of the human microcirculation in health and disease. Although ceramide-induced upregulation of H 2 O 2 preserves flow-induced vasodilation, it may produce chronic structural changes in microcirculatory vessels. The finding that short-term inhibition of the ceramide-producing enzyme, neutral sphingomyelinase, reverts the mediator of flow-induced dilation back to NO in arterioles from patients with CAD is encouraging and may set the stage for new therapeutic opportunities to restore endothelial vasomotor function in patients.
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